Back to Journals » Clinical Interventions in Aging » Volume 7

Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study

Authors Rinaldi S , Maioli M, Santaniello S, Castagna A , Pigliaru, Gualini, Lotti M, Carta, Fontani V , Ventura C 

Received 26 April 2012

Accepted for publication 16 May 2012

Published 29 June 2012 Volume 2012:7 Pages 191—194


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,7

1Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neuro Psycho Physio Pathology and Neuro Psycho Physical Optimization, Rinaldi Fontani Institute, Florence; 3Department of Biomedical Sciences, University of Sassari, Sassari; 4Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems, Bologna; 5Department of Information Technology and Statistical Analysis, Rinaldi Fontani Institute, Florence; 6Ophthalmology Section, University of Parma, Parma; 7Cardiovascular Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy

Background: Beta-galactosidase is the most widely used biomarker for highlighting the processes of cellular aging, including neurodegeneration. On this basis, we decided to test in vitro whether a set of rescuing/reparative events previously observed by us in subjects treated with radioelectric asymmetric conveyor (REAC) technology may also involve antagonism of a marker of aging-related degenerative processes, as assessed by a reduction in beta-galactosidase at the cellular level.
Methods: Human adipose-derived stem cells were cultured at different passages, ranging from 5 to 20, with or without REAC exposure for 12 hours. The cells were then processed for biochemical beta-galactosidase staining and morphological microscopy analysis.
Results: We observed a significant reduction in expression of senescence associated-beta-galactosidase, and a persistence of fibroblast-like morphology typical of human adipose-derived stem cells, even at late passages.
Conclusion: Our results indicate the ability of REAC technology to counteract in vitro senescence of human adipose-derived stem cells, and prompt the hypothesis that such technology may be exploited to antagonize in vivo senescence of tissue-resident or transplanted stem cells playing an important role in clinical treatment of age-related processes.

Keywords: aging, adipose-derived stem cells, neurodegenerative diseases

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.